Rosacea: More Than Skin Deep — The Inflammatory, Autoimmune, and Systemic Disease Connections

For decades, rosacea was dismissed as a cosmetic nuisance — a bit of redness, some flushing, maybe a few bumps. But a growing body of research is revealing something far more significant: rosacea is a chronic inflammatory disease with systemic implications that extend well beyond the face. It is associated with autoimmune conditions, cancer, cardiovascular risk, gastrointestinal disease, and even neurodegeneration.

Here's what the science actually says.

Is Rosacea an Autoimmune Disease?

Rosacea is not formally classified as an autoimmune disease. It is classified as a chronic inflammatory skin disorder characterized by facial erythema, telangiectasia, papules, pustules, and ocular manifestations. Its pathogenesis involves a complex interplay of genetic, environmental, immune, microbial, and neurovascular factors.

However, rosacea shares striking immunological features with autoimmune conditions. The disease involves dysregulation of both the innate and adaptive immune systems, with abnormal infiltration of Th1/Th17 cells, macrophages, mast cells, and neutrophils in affected skin. Key inflammatory pathways — including TLR2/LL-37/mTORC1 signaling, NF-κB activation, inflammasome assembly, and IL-17/JAK-STAT signaling — drive a self-perpetuating cycle of inflammation and angiogenesis.

Importantly, rosacea shares genetic risk loci with classic autoimmune diseases. Genes in the HLA complex — the same gene family central to autoimmune recognition — are implicated in rosacea susceptibility. A landmark 2016 Danish population-based study by Egeberg et al. found that rosacea patients had significantly increased odds of:

- Type 1 diabetes mellitus (OR 2.59, 95% CI 1.41–4.73)

- Celiac disease (OR 2.03, 95% CI 1.35–3.07)

- Multiple sclerosis (OR 1.65, 95% CI 1.20–2.28)

- Rheumatoid arthritis (OR 2.14, 95% CI 1.82–2.52)

These associations were strongest in women. The authors noted that a genome-wide association study had identified 90 genetic regions associated with these four autoimmune diseases, and rosacea appears to share some of this genetic architecture.

Even early research from 1982 by Manna et al. found that rosacea patients had a higher incidence of autoimmune-type disorders, were harder to sensitize to DNCB (suggesting altered cell-mediated immunity), and showed immunoglobulin and complement deposits at the dermo-epidermal junction — features reminiscent of autoimmune skin diseases.

Bottom line: Rosacea is not technically an autoimmune disease, but it behaves like one in many respects and clusters with autoimmune conditions at a rate that cannot be ignored.

Is Rosacea an Inflammatory Condition?

Unequivocally, yes. This is no longer debated. Rosacea is fundamentally an inflammatory disease — and the inflammation is not limited to the skin.

A 2023 study by Karaosmanoglu et al. measured systemic inflammatory markers in rosacea patients versus controls and found significantly elevated:

- C-reactive protein (CRP)

- Erythrocyte sedimentation rate (ESR)

- Systemic immune inflammation (SII) index

- Monocyte and platelet counts

A 2025 study by Koç et al. confirmed these findings and demonstrated that the CRP/albumin ratio (CAR) correlated with rosacea severity, with an AUC of 0.83 for distinguishing rosacea patients from controls.

A 2026 proteomic study by Huang et al. identified 490 differentially expressed serum proteins in rosacea patients (431 upregulated), enriched in inflammatory pathways including PI3K-Akt, IL-17, and cholesterol metabolism. The authors concluded that rosacea should be considered a "systemic inflammatory disorder."

Cutaneous biomarker analysis by Wienholtz et al. (2026) found elevated levels of IL-1RA, IL-8, IL-12p70, IL-17A, IL-17E, IL-17F, IL-18, IL-22, IP-10, VEGF-α, and IFN-γ in rosacea skin, with increasing severity correlating with higher concentrations of IFN-γ, IL-18, IP-10, VEGF-α, and IL-17F.

The inflammatory cascade in rosacea involves virtually every major inflammatory pathway: TLR2 activation, LL-37 cathelicidin overexpression, NF-κB signaling, NLRP3 inflammasome activation, TNF-α/IL-6/IL-1β release, mast cell degranulation, and VEGF-driven angiogenesis.

Does Rosacea Increase Your Risk of Cancer?

This is where the data gets particularly interesting — and somewhat conflicting depending on the cancer type and population studied.

Skin Cancer:

- A 2022 Korean nationwide cohort study (Cho et al., n = 11,420) found rosacea patients had a significantly increased risk of actinic keratosis (aHR 6.05, 95% CI 3.63–10.09) and keratinocyte carcinoma (aHR 2.66, 95% CI 1.53–4.61).

- The Nurses' Health Study II (Li et al., 2015, n = 75,088) found rosacea was associated with an elevated risk of basal cell carcinoma (HR 1.50, 95% CI 1.35–1.67).

- A 2024 German real-world cohort study (von Stebut et al., n = 122,444 per group) found a striking association with malignant melanoma in Caucasians (OR 6.02, 95% CI 5.76–6.32), though this association was absent in Asian patients. This finding requires replication and may be confounded by shared UV exposure and skin type.

Internal Cancers:

- The Danish nationwide cohort (Egeberg et al., 2017, n = 49,475 rosacea patients) found increased risk of non-melanoma skin cancer (HR 1.36), breast cancer (HR 1.25), and hepatic cancer (HR 1.42), with a decreased risk of lung cancer (HR 0.78).

- The Nurses' Health Study II found a possible association with thyroid cancer (HR 1.59, 95% CI 1.07–2.36) but no significant associations with other internal malignancies.

- The Korean study found no increased risk of melanoma, gastric, colorectal, or liver cancer.

The inconsistencies across studies likely reflect differences in populations, confounders (especially UV exposure and skin phototype), and study design. The skin cancer associations may be partly explained by shared risk factors (fair skin, UV sensitivity) rather than a direct inflammatory mechanism.

Cardiovascular and Metabolic Risk

A systematic review and meta-analysis by Chen et al. (2020, 13 studies, 50,442 rosacea patients) found that rosacea was associated with:

- Higher prevalence of hypertension and dyslipidemia

- Higher total cholesterol, LDL, triglycerides, systolic and diastolic blood pressure, and fasting blood glucose

A separate meta-analysis by Tsai et al. (2020, 12 studies, 40,752 patients) confirmed these findings and additionally found elevated C-reactive protein, greater epicardial fat thickness, and higher rates of insulin resistance (OR 2.34) in rosacea patients.

Rainer et al. (2015) demonstrated that these cardiometabolic associations were severity-dependent — moderate to severe rosacea was significantly more associated with hyperlipidemia, hypertension, metabolic diseases, and cardiovascular diseases than mild rosacea.

The comprehensive systematic review by Haber and El Gemayel (2018, 29 studies) confirmed significant associations between rosacea and hypertension (n = 18,176), cardiovascular diseases (n = 9,739), dyslipidemia (n = 7,004), and diabetes mellitus (n = 6,306).

Gastrointestinal Disease

The gut-skin axis in rosacea is one of the most active areas of research. A Danish nationwide cohort study by Egeberg et al. (2017) found rosacea was significantly associated with:

- Celiac disease (HR 1.46)

- Crohn's disease (HR 1.45)

- Ulcerative colitis (HR 1.19)

- Irritable bowel syndrome (HR 1.34)

A 2024 study using the diverse US-based All of Us database (Piontkowski et al., 8,319 rosacea patients) confirmed and expanded these findings with even stronger associations: IBS (OR 2.35), GERD (OR 2.07), celiac disease (OR 1.93), Crohn's disease (OR 1.82), and H. pylori-associated disease (OR 1.79).

A meta-analysis by Wang and Chi (2019) pooling cohort studies confirmed significantly increased risk of both Crohn's disease (pooled HR 1.58) and ulcerative colitis (pooled HR 1.18) in rosacea patients.

Mendelian randomization analysis by Li et al. (2023) provided evidence for a causal effect of IBD on rosacea (but not vice versa), suggesting that gut inflammation may drive skin disease through shared immunological pathways.

Neurodegeneration: Dementia, Alzheimer's, and Parkinson's Disease

Perhaps the most surprising comorbidity cluster involves neurodegenerative diseases. A landmark Danish study by Egeberg et al. (2016, n = 5.6 million) found:

- Rosacea was associated with an increased risk of dementia (aHR 1.07) and Alzheimer's disease (aHR 1.25)

- When limited to dermatologist-confirmed rosacea, the risk of Alzheimer's disease nearly doubled (aHR 1.92, 95% CI 1.44–2.58)

A separate Danish nationwide study by the same group found rosacea was an independent risk factor for Parkinson's disease (adjusted IRR 1.71, 95% CI 1.52–1.92), with ocular rosacea carrying a 2-fold increased risk (IRR 2.03). Intriguingly, tetracycline therapy appeared to modestly reduce Parkinson's risk.

The proposed mechanism involves shared upregulation of matrix metalloproteinases (MMPs) and antimicrobial peptides in both rosacea and neurodegenerative diseases. Bioinformatic analyses have identified 747 overlapping differentially expressed genes between Alzheimer's disease and rosacea, enriched in inflammation, metabolism, and apoptosis pathways. Shared regulatory proteins include SNCA (α-synuclein), GSK3B, and HSPA8.

Psychiatric Comorbidities

The systematic review by Haber and El Gemayel (2018) identified depression as the most commonly associated comorbidity (n = 117,848 patients across studies), followed by anxiety disorder (n = 9,079). Mendelian randomization by Hu et al. (2025) provided evidence for a causal relationship between rosacea and depression (OR 1.0015, P = 0.02), though the effect size was small.

The Big Picture: Rosacea as a Systemic Disease

Wollina (2019) argued explicitly that rosacea should be considered a systemic disease, given its associations with metabolic, psychiatric, neurologic, gastrointestinal, and malignant conditions. A 2026 review by Shi et al. framed rosacea within the skin-gut-brain axis, proposing that neurohormonal-immune dysregulation connects the cutaneous, gastrointestinal, and neurological manifestations.

The emerging proteomic evidence further supports this view. Huang et al. (2026) identified two distinct molecular endotypes of rosacea — an inflammatory-predominant subtype and a neurogenic-metabolic subtype — establishing rosacea as a heterogeneous systemic inflammatory disorder rather than a simple skin condition.

Key Publications Referenced

Pathogenesis and Inflammatory Mechanisms:

- Yang et al. "Signaling Pathways and Targeted Therapy for Rosacea." Frontiers in Immunology, 2024.

- Wang & Zhou. "Advances in the Pathogenesis of Rosacea." Frontiers in Immunology, 2025.

- Steinhoff et al. "New Insights Into Rosacea Pathophysiology." JAAD, 2013.

- van Zuuren. "Rosacea." NEJM, 2017.

- Karaosmanoglu et al. "Evaluation of Inflammatory Status in Blood in Patients With Rosacea." Scientific Reports, 2023.

- Koç et al. "The Relationship of Disease Severity With CRP/Albumin Ratio in Rosacea." Archives of Dermatological Research, 2025.

- Huang et al. "Proteomic Profiling Reveals Distinct Inflammatory and Neurogenic Endotypes in Rosacea." JAAD, 2026.

- Wienholtz et al. "Cutaneous Inflammatory Biomarkers in Rosacea." Clinical and Experimental Dermatology, 2026.

- Shi et al. "Neurohormonal-Immune Dysregulation in Rosacea." Drug Design, Development and Therapy, 2026.

Autoimmune Associations:

- Egeberg et al. "Clustering of Autoimmune Diseases in Patients With Rosacea." JAAD, 2016.

- Manna et al. "Involvement of Immune Mechanisms in the Pathogenesis of Rosacea." British Journal of Dermatology, 1982.

- Wang & Zhang. "Exploring Immune-Related Genes and Mechanisms in Rosacea." BioMed Research International, 2026.

Cancer Risk:

- Cho et al. "Risk of Skin Cancer and Actinic Keratosis in Patients With Rosacea." Acta Dermato-Venereologica, 2022.

- Li et al. "Personal History of Rosacea and Risk of Incident Cancer Among Women." British Journal of Cancer, 2015.

- Egeberg et al. "Rosacea and Risk of Cancer in Denmark." Cancer Epidemiology, 2017.

- von Stebut et al. "Rosacea Is Strongly Associated With Melanoma in Caucasians." Scientific Reports, 2024.

Cardiovascular and Metabolic Risk:

- Chen et al. "Association Between Rosacea and Cardiometabolic Disease." JAAD, 2020.

- Tsai et al. "Cardiovascular Risk and Comorbidities in Patients With Rosacea." Acta Dermato-Venereologica, 2020.

- Rainer et al. "Rosacea Is Associated With Chronic Systemic Diseases in a Skin Severity-Dependent Manner." JAAD, 2015.

Gastrointestinal Associations:

- Egeberg et al. "Rosacea and Gastrointestinal Disorders." British Journal of Dermatology, 2017.

- Piontkowski et al. "Rosacea and Gastrointestinal Diseases: All of Us Database." Dermatology, 2024.

- Wang & Chi. "Association of Rosacea With Inflammatory Bowel Disease: A Meta-Analysis." Medicine, 2019.

- Li et al. "Detecting Potential Causal Relationship Between IBD and Rosacea Using Mendelian Randomization." Scientific Reports, 2023.

- Spoendlin et al. "Rosacea in Patients With UC and CD." Inflammatory Bowel Diseases, 2016.

Neurodegenerative Associations:

- Egeberg et al. "Patients With Rosacea Have Increased Risk of Dementia." Annals of Neurology, 2016.

- Egeberg et al. "Exploring the Association Between Rosacea and Parkinson Disease." JAMA Neurology, 2016.

- Zhang et al. "Bioinformatics Identify the Therapeutic Role of Melatonin in AD and Rosacea." Frontiers in Immunology, 2021.

- Grech et al. "From Skin to Brain: Key Genetic Mediators." Genes, 2025.

Comprehensive Comorbidity Reviews:

- Haber & El Gemayel. "Comorbidities in Rosacea: A Systematic Review." JAAD, 2018.

- Wollina. "Is Rosacea a Systemic Disease?" Clinics in Dermatology, 2019.

- Vera et al. "Rosacea Comorbidities." Dermatologic Clinics, 2018.

- Wang & Chi. "Rosacea, Germs, and Bowels: A Review on GI Comorbidities." Advances in Therapy, 2021.

- Frazier et al. "Rosacea: Common Questions and Answers." American Family Physician, 2024.